Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial.
Gionchetti
P
P
Rizzello
F
F
Ferrieri
A
A
Venturi
A
A
Brignola
C
C
Ferretti
M
M
Peruzzo
S
S
Miglioli
M
M
Campieri
M
M
D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000378:metabolism; D004311:Double-Blind Method; D005765:Gastrointestinal Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D010865:Pilot Projects; D010919:Placebos; D012294:Rifamycins / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000078262:Rifaximin
D005765:Gastrointestinal Agents; D010919:Placebos; D012294:Rifamycins; D000078262:Rifaximin